November 18, 2013
The Role of the Board in the IPO Process
Recently IPO or looking to go public in the next 12-18 months? Then you don’t want to miss the Pre- and Post-IPO Board Forum, hosted by…
Posted by
Safeguard Insights
November 18, 2013
November 13, 2013
30 percent of Safeguard’s Partner Companies Ranked on the Deloitte Technology Fast 500
The numbers are in. And we’re excited to announce that six of Safeguard’s partner companies have been named to the Deloitte Technology Fast 500TMList for…
Posted by
October 24, 2013
RECAP: Safeguard Scientifics Third Quarter 2013 Financial Results
Safeguard announced third quarter 2013 financial results and reiterated increased aggregate partner company revenue guidance for 2013 to a range of $285 million to $295 million, up…
Posted by
October 7, 2013
Safeguard Increases Aggregate Partner Company Revenue Guidance for 2013
Safeguard announced that it has increased 2013 aggregate partner company revenue guidance to a range of $285 million to $295 million, up from its initial…
Posted by
October 7, 2013
Safeguard Announces Final Agenda and Webcast for Investor Day 2013
Safeguard announced the final agenda and webcast information for Investor Day 2013. The event will be held at the New York Stock Exchange tomorrow, October…
Posted by
September 25, 2013
Why the Rocket Fuel IPO is good news for MediaMath
Shares of Rocket Fuel (NASDAQ: FUEL) literally took off on its first day as a publicly traded company. After pricing at the high end of the expected…
Posted by
September 20, 2013
Forever Young: Safeguard celebrates its 60th birthday with an enduring spirit of entrepreneurship
In 1953, the average cost of a new home was $9,550. Gas was 20 cents a gallon, and the average annual wage was $4,000. The…
Posted by
July 26, 2013
RECAP: Safeguard Scientifics Second Quarter 2013 Financial Results
Safeguard’s partner companies remain on track to achieve growth and operating, financial and strategic milestones. As a result, Safeguard reiterated aggregate partner company revenue guidance…
Posted by
July 24, 2013
Why VC Interest in Biotechnology Companies Jumped in the Second Quarter of 2013
The second quarter 2013 NVCA numbers came in, and while capital deployments in medical device companies declined 1 percent in both dollars and deals from…
Posted by
